Authors:
Kurz, C
Hefler, L
Zeisler, H
Schatten, C
Husslein, P
Tempfer, C
Citation: C. Kurz et al., Maternal basic fibroblast growth factor serum levels are associated with pregnancy-induced hypertension, J SOC GYN I, 8(1), 2001, pp. 24-26
Authors:
Bancher-Todesca, D
Hefler, L
Zeisler, H
Schatten, C
Husslein, P
Heinze, G
Tempfer, C
Citation: D. Bancher-todesca et al., Placental expression of cytokeratin 18 and serum levels of tissue polypeptide antigen in women with pregnancy-induced hypertension, HYPERTENS P, 20(1), 2001, pp. 89-98
Authors:
Tempfer, C
Unfried, G
Zeillinger, R
Hefler, L
Nagele, F
Huber, JC
Citation: C. Tempfer et al., Endothelial nitric oxide synthase gene polymorphism in women with idiopathic recurrent miscarriage, HUM REPR, 16(8), 2001, pp. 1644-1647
Authors:
Muller-Klingspor, V
Hefler, L
Obermair, A
Kaider, A
Breitenecker, G
Leodolter, S
Kohlberger, P
Citation: V. Muller-klingspor et al., Prognostic value of beta 1-integrin (=CD29) in serous adenocarcinomas of the ovary, ANTICANC R, 21(3C), 2001, pp. 2185-2188
Authors:
Mayerhofer, K
Bodner, K
Saletu, B
Bodner-Adler, B
Anderer, P
Hefler, L
Schindl, M
Kaider, A
Leodolter, S
Kainz, C
Citation: K. Mayerhofer et al., Paclitaxel-carboplatin chemotherapy does not cause encephalopathy in patients with ovarian cancer: A prospective EEG mapping study in 28 patients, ANTICANC R, 21(1B), 2001, pp. 803-808
Authors:
Bodner-Adler, B
Hefler, L
Bodner, K
Leodolter, S
Frischmuth, K
Kainz, C
Mayerhofer, K
Citation: B. Bodner-adler et al., Serum levels of angiogenin (ANG) in invasive cervical cancer and in cervical intraepithelial neoplasia (CIN), ANTICANC R, 21(1B), 2001, pp. 809-812
Authors:
Lebrecht, A
Hefler, L
Tempfer, C
Koelbl, H
Citation: A. Lebrecht et al., Serum cytokine concentrations in patients with cervical cancer: Interleukin-4, interferon-gamma, and monocyte chemoattractant protein-1, GYNECOL ONC, 83(1), 2001, pp. 170-171
Authors:
Mayerhofer, K
Bodner, K
Bodner-Adler, B
Schindl, M
Kaider, A
Hefler, L
Zeillinger, R
Leodolter, S
Joura, EA
Kainz, C
Citation: K. Mayerhofer et al., Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy, CANCER, 91(2), 2001, pp. 388-393
Authors:
Hefler, L
Tempfer, C
Frischmuth, K
Maenner, G
Concin, N
Sliutz, G
Reinthaller, A
Leodolter, S
Kainz, C
Citation: L. Hefler et al., Serum concentrations of tissue polypeptide antigen in patients with vulvarintraepithelial neoplasia and vulvar cancer, TUMOR BIOL, 21(2), 2000, pp. 98-104
Authors:
Mayerhofer, K
Bodner-Adler, B
Bodner, K
Saletu, B
Schindl, M
Kaider, A
Hefler, L
Leodolter, S
Kainz, C
Citation: K. Mayerhofer et al., A paclitaxel-containing chemotherapy does not cause central nervous adverse effects: A prospective study in patients with ovarian cancer, ANTICANC R, 20(5C), 2000, pp. 4051-4055
Authors:
Mayerhofer, K
Bodner, K
Saletu, B
Bodner-Adler, B
Anderer, P
Hefler, L
Kaider, A
Leodolter, S
Kainz, C
Citation: K. Mayerhofer et al., Paclitaxel does not cause central nervous adverse effects: A prospective vigilance-controlled EEG mapping study in ovarian cancer patients, WIEN KLIN W, 112(23), 2000, pp. 1007-1013
Authors:
Tempfer, C
Zeisler, H
Hefler, L
Schatten, C
Husslein, P
Kainz, C
Citation: C. Tempfer et al., Serum levels of ELAM-1, but not CD44, predict the clinical outcome of patients with preeclampsia, HYPERTENS P, 18(1), 1999, pp. 45-55
Authors:
Obermair, A
Hefler, L
Nather, A
Preyer, O
Kaider, A
Citation: A. Obermair et al., Correlation of the serum concentration of vascular endothelial growth factor (VEGF) and hemoglobin levels in patients with epithelial ovarian cancer, ANN ONCOL, 10(8), 1999, pp. 998-998
Authors:
Moser, PL
Kieback, DG
Hefler, L
Tempfer, C
Neunteufel, W
Gitsch, G
Citation: Pl. Moser et al., Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer, ANTICANC R, 19(5C), 1999, pp. 4391-4393
Authors:
Moser, PL
Hefler, L
Tempfer, C
Neunteufel, W
Kieback, DG
Gitsch, G
Citation: Pl. Moser et al., Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer, ANTICANC R, 19(3B), 1999, pp. 2365-2367